You are here

Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Porto Alegre, RS, 90610-000 Brazil
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject who completed the A1481244 study and are judged by the Investigator to derive
clinical benefit from continuous treatment with Sildenafil 20 mg therapy.

- Subject who resides in a Brazilian State where Sildenafil is not supplied by State
Health Secretary.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant or lactating women.

- Current participation in other studies and during study participation.

NCT00866983
Pfizer
No longer available
Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pulmonary Arterial Hypertension
NCT01897740
All Genders
10+
Years
Moscow,
Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT00878943
All Genders
18+
Years
Multiple Sites
Glaucoma, Ocular Hypertension
NCT00950690
All Genders
18+
Years
Multiple Sites
Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio? is not supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit from continued treatment with Sildenafil. It will be supplied until patient gets access to Sildenafil through Brazilian State Health Secretary from where patient resides.
Not Provided
Expanded Access
Drug: sildenafil (Revatio) 20 mg TID
To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio? is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
Other Name: sildenafil, Revatio
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Brazil
 
 
NCT00866983
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now